ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2028

Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus

Qing Zhang1 and Huilin Zhang 2, 1Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic), 2Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: systemic lupus erythematosus (SLE) and T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: T follicular helper cells (Tfh cells) are a newly discovered subset of CD4+ T cells, which play a mainly role in inducing B cells to produce antibody. Tfh cells are over activated in systemic lupus erythematosus (SLE) patients, consequently bring about immune damages. Hematopoietic progenitor kinase 1 (HPK1) can inhibit T cell-mediated immune responses, but the role that HPK1 plays in Tfh cells from SLE patients remain elusive. The aim of this study is to investigate whether HPK1 plays roles in SLE Tfh cells.

Methods: Naïve CD4+ T cells and B cells were isolated from healthy controls and SLE patients. Then Naïve CD4+ T cells were induced to differentiate into Tfh cells by stimulating with anti-CD3 antibody, anti-CD28 antibody, IL-6, IL-12, IL-21, and TGF-β. HPK1 mRNA and protein levels in Tfh cells were determined by real-time RT-PCR and western blotting. Detection of IL-21, CXCL13, IFNγ, IL-17A, IgM, IgG1, IgG2a, IgG2b and IgG3 levels were performed by ELISA. Tfh cells proliferations were analyzed with MTT assay.

Results: We identified HPK1 mRNA and protein levels were significantly decreased in Tfh cells from patients with SLE. Moreover, HPK1 mRNA levels were found to negatively correlated with SLE disease activity as measured by SLE Disease Activity Index (SLEDAI). Down-regulation of HPK1 in healthy Tfh cells significantly accelerated Tfh cells proliferation and productions of IL-21, CXCL13, IFNγ, IgG1, IgG2a, IgG2b, and IgG3. There were no marked changes in IL-17A and IgM amounts. Consistent with these findings, overexpressing HPK1 in SLE Tfh cells caused significant decrease in Tfh cells proliferation and productions of IL-21, CXCL13, IFNγ, IgG1, IgG2a, IgG2b, and IgG3. And there were no significant alters in IL-17A and IgM levels.

Conclusion: Our results show for the first time that inhibited expression of HPK1 in SLE Tfh cells contributes to Tfh cells overactivation and B cells overstimulation, which lead to the development of SLE at last.


Disclosure: Q. Zhang, None; H. Zhang, None.

To cite this abstract in AMA style:

Zhang Q, Zhang H. Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/inhibited-expression-of-hematopoietic-progenitor-kinase-1-in-tfh-cells-contributes-to-autoimmunity-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibited-expression-of-hematopoietic-progenitor-kinase-1-in-tfh-cells-contributes-to-autoimmunity-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology